Dermira

Marketing

Eli Lilly, Incyte's Olumiant notches atopic dermatitis trial win

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?
Kyle Blankenship Jan 27, 2020 10:30am

Lilly inks $1.1B Dermira deal as biopharma M&A gets underway

Jan 10, 2020 11:42am

Condé Nast's new digital buying plan scores with pharma

Dec 16, 2019 7:53am

Can Dupixent steal half of a $21B eczema market? Not so fast

Dec 11, 2019 10:42am

Amgen, GSK advance to #FierceMadness Elite 8

Mar 27, 2019 10:55am

Dermira taps real patients in first ads for Qbrexza

Mar 25, 2019 10:11am